Elephas Biosciences and Tes Pharma Partnered on Cancer Drug

The companies have launched a research collaboration to evaluate the investigational therapy TES-4207 for lung cancer treatment.

Updated on Sept. 24, 2026 in Cancer

A close-up view of a polished stainless steel laboratory tool used in clinical tissue analysis on a sterile metal surface.
Elephas Biosciences and Tes Pharma have entered a research partnership to evaluate the efficacy of the investigational lung cancer therapy TES-4207. AI Illustration. Upload story photo >

Live Poll

Do you believe pharmaceutical research partnerships generally improve the development of new cancer therapies?

Elephas Biosciences and Tes Pharma have entered a collaboration to study the efficacy of TES-4207 in patients with non-small cell lung cancer. Researchers will use the elive platform to analyze functional responses to the therapy in human tumor tissue.

Why it matters

The partnership aims to inform the clinical development of TES-4207 by characterizing response phenotypes in live tissue. This approach helps researchers understand how the treatment affects the tumor microenvironment.

The collaboration centers on TES-4207, an investigational therapy that targets NR2F6 for the treatment of non-small cell lung cancer. The study remains in the early translational research phase.

The players

Elephas Biosciences

This company is a Wisconsin-based biotech firm specializing in functional imaging platforms to improve cancer drug discovery.

Tes Pharma

This Italian pharmaceutical company focuses on the development of novel therapies, including those targeting nuclear receptors for oncology.

The details

Elephas Biosciences, based in Madison, Wisconsin, provides its proprietary elive platform to measure functional responses in live tumor tissue. This technology is designed to preserve the native tumor microenvironment extracted via core needle biopsy.

Timeline

  1. September 24, 2026: The companies officially announced the research collaboration.

The Big Picture

The collaboration leverages the elive platform functional response measurement system to bridge the gap between initial drug discovery and clinical trial outcomes. This partnership serves as a practical application of the elive platform to accelerate the evaluation of a specific therapeutic candidate.

The partnership does not yet affect current patient treatment options or standard of care for lung cancer. Future clinical development of TES-4207 may eventually provide new therapeutic pathways for patients with non-small cell lung cancer.

The takeaway

This collaboration highlights the increasing use of live-tissue analysis in preclinical oncology research. Such methods aim to improve the predictive accuracy of drug responses before expensive and lengthy clinical trials begin.

Further reading

Learn more about the latest innovations in oncology research in our Cancer section.

Source note: This article includes information reported by Firstwordpharma.

Live Poll

Do you believe pharmaceutical research partnerships generally improve the development of new cancer therapies?